1
|
Tannir NM, Dubauskas Lim Z, Bekele BN, Johnson ED, Tamboli P, Vaishampayan UN, Plimack ER, Rathmell K, Jonasch E. Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.386] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
386 Background: RMC is a rare, highly aggressive primary neoplasm of the kidney that almost exclusively afflicts young black pts with sickle cell hemoglobinopathies, primarily sickle cell trait. The primary objectives of this study were to evaluate the clinical characteristics and treatment outcome of RMC pts. Methods: We retrospectively reviewed the medical records of pts diagnosed with RMC at four US institutions between 2000 and 2010. Overall survival (OS) was determined from initial diagnosis to date of death or last follow up (F/U). The time interval from date of metastasis to death or last F/U (OSm) was also determined. Kaplan-Meier methods were used to estimate OS and OSm. Results: 20 RMC pts were identified. All pts were black; 14 (70%) were males; 18 had sickle cell trait, 1 had sickle thalassemia and 1 not tested. 19 presented with stages III or IV; 7 (35%) had nephrectomy. Nineteen pts had ≥ 2 metastatic sites. Twelve pts had performance status [PS] 0/1; eight pts had PS 2/3. For the OS analysis, data on 16 pts were available and for the OSm analysis, data on 20 pts were available. The median follow up time for the OS analysis was 722 days. Thirteen of 16 pts died with median OS of 421 days [95%CI: 225–546]. Sixteen of 20 pts died in the OSm analysis with median OSm of 378 days [95%CI: 225–487]. Frontline therapy consisted of TT [sunitinib (5), bevacizumab + erlotinib (1), imatinib (2)], chemotherapy (C) [platinum/gemcitabine or taxane (7), gemcitabine/doxorubicin (2)], C + TT [gemcitabine/cisplatinum/bevacizumab (2), imatinib/doxorubicin (1)]. Three pts achieved a partial response (PR) in first-line (2 with C, 1 with C + TT). Twelve pts received second-line systemic therapies; 4 achieved PR (1 with bevacizumab/erlotinib, 2 with C, 1 with C + TT). Among 15 pts who had TT at any time during their treatment course, only 1 pt had PR. Conclusions: The prognosis of RMC pts remains poor despite initial palliation with systemic therapy. Collaborative multi-institutional efforts are needed to better understand the biology of this disease and improve treatment strategies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. M. Tannir
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - Z. Dubauskas Lim
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - B. N. Bekele
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - E. D. Johnson
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - P. Tamboli
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - U. N. Vaishampayan
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - E. R. Plimack
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - K. Rathmell
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - E. Jonasch
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Fox Chase Cancer Center, Philadelphia, PA; University of North Carolina at Chapel Hill, Chapel Hill, NC
| |
Collapse
|
2
|
Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|